| Literature DB >> 27011160 |
Hyun Woo Jeon1, Jae Kil Park1, Kyo Young Song2, Sook Whan Sung1.
Abstract
BACKGROUND: Minimally invasive esophagectomy (MIE) has the potential to reduce the morbidity and mortality of esophageal cancer surgery. Esophageal squamous cell carcinoma (ESCC) has a high incidence of earlier lymphatic spread and is usually located more proximal to the incisor than esophageal adenocarcinoma; consequently, the anastomosis should be made more proximal in the thorax or in the neck. We adopted the proximal intrathoracic anastomotic technique using thoracoscopy for mid-to-lower ESCC.Entities:
Mesh:
Year: 2016 PMID: 27011160 PMCID: PMC4807006 DOI: 10.1371/journal.pone.0152151
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The port incision including a 6cm utility incision.
A 10.5 mm port was placed in the mid-axillary line of the 7th intercostal space for insertion of the 30° camera. A utility incision was made at the anterior axillary line of the 5th or 6th intercostal space. A 10.5 mm port was placed below the scapular tip. A 10.5 mm port was placed at the anterior axillary line of the 3rd intercostal space.
Fig 2Anastomotic technique for the thoracoscopic Ivor Lewis procedure.
(a) Single muscular purse string suture on the proximal esophagus. (b) The anvil of a 28-mm circular stapler was placed in the proximal esophagus. (c) EEA body insertion into the gastric conduit was performed inside the chest under thoracoscopy. (d) High intrathoracic anastomosis was carried out.
Baseline Patient Characteristics.
| Characteristic | Total (n = 58) |
|---|---|
| Mean±SD (cm) or n (%) | |
| Age | 64.3±9 |
| Gender | Male: 54(93.1) |
| HBP | 24 (41.4) |
| Current smoker | 17 (29.3) |
| Tumor location | 30.9±4.1 |
| Clinical stage | |
| Stage I | 31 (53.4) |
| Stage II | 18 (31.0) |
| Stage III | 9 (15.5) |
Data were presented as the mean±SD or frequencies and percentages as appropriate
HBP: Hypertension
Operative data.
| Variable | Value |
|---|---|
| Mean±SD or n(%) | |
| Operative time (minutes) | |
| Total surgery time | 371.8±51.6 |
| Thoracoscopic time | 254.8±38.3 |
| R0 resection (%) | 58 (100) |
| Conversion to thoracotomy (%) | None |
| Length of proximal resection margin (cm) | 5.2±2.3 |
| Number of lymph node dissected | 31±11.7 |
| Tumor size (cm) | 2.8±1.6 |
| pStage | |
| p/yp Stage I | 26/2 (48.3) |
| p/yp Stage II | 16/3 (32.8) |
| p/yp Stage III | 8/3 (18.9) |
| ICU stay (hours) | 3.5±8.2 |
| Hospital stay (days) | 13.6±7.4 |
| The level of anastomosis from incisor (cm) | 22.3±1.8 |
Data were presented as the mean±SD or frequencies and percentages as appropriate
R0 resection: complete resection without residual tumor, p stage: Pathologic stage, yp stage: pathologic stage after neoadjuvant treatment. ICU:Intensive care unit.
Morbidity and mortality of a High Intrathoracic Anastomosis under Thoracoscopy.
| Complications | Number (%) |
|---|---|
| Transfusion | 2 (3.4) |
| Pneumonia | 1 (1.7) |
| Empyema | None |
| Chylothorax | None |
| Atrial fibrillation | 2 (3.4) |
| Vocal cord injury | 9 (15.5) |
| Prolonged air leakage | None |
| Anastomotic leakage | 3 (5.2) |
| Stricture | 5 (8.6) |
| Bowel obstruction | 1 (1.7) |
| Death | 1 (1.7) |
Follow up period for oncologic results in 57 patients.
| Number (%) | |
|---|---|
| Death | 2 (3.5) |
| Cerebral infarction | 1 (1.8) |
| Pneumonia during adjuvant treatment | 1 (1.8) |
| Local recurrence at the anastomosis | 1 (1.8) |
| Distant metastasis | 9 (15.8) |
| Supraclavicular lymph node | 2 (3.5) |
| Brain | 1 (1.8) |
| Bone | 2 (3.5) |
| Liver | 4 (7.0) |
Comparison data form literature.
| Our study. | Palazzo et al. | ECOG study | Hsu PK et al. | |
|---|---|---|---|---|
| Number | 58 | 104 | 104 | 66 |
| Age (m or SD) | 64.3±9 | 62.3 (31–86) | 65 (36–83) | 58.8 ±10.4 |
| Complete resection(%) | 58 (100%) | 101 (97.1) | 99 (96.1%) | 64 (97%) |
| Operation time (m or SD) | 371.8±51.6 | 330 | 510.9 ± 121.3 | |
| Number of LN (m or SD or median) | 31±11.7 | 21 (3–57) | 19 (2–55) | 28.3 ± 16.6 |
| Stage I (%) | 28 (48.3) | 72 (69.2) | 40 (38.5) | 16 (24.2) |
| Leakage (%) | 3 (5.2) | 21 (20.2) | 9 (8.6) | 18 (27.3) |
| Pneumonia (%) | 1 (1.7) | 7 (6.7) | 4 (3.8) | 7 (10.6) |
| 30 day death (%) | 1 (1.7) | 2 (1.9) | 5 (7.6) | |
| F/U period | 24 | 29.3 | 35.8 | 23.0 ±13.2 |
| Recurrence (%) | 10 (17.5) | 21 (21) | 29 (27.9) | 20 (32.8) |
ECOG: the Eastern Cooperative Oncology Group. F/U period: Follow up period.